Nexalin Technology Files S-1 for Public Offering
Ticker: NXL · Form: S-1 · Filed: Dec 20, 2024 · CIK: 1527352
Sentiment: neutral
Topics: ipo, registration-statement, healthcare-technology
TL;DR
Nexalin Tech (NXLN?) filing S-1, prepping for IPO. Get ready.
AI Summary
Nexalin Technology, Inc., a Delaware-based company specializing in electromedical apparatus, filed an S-1 registration statement on December 20, 2024. The company, located at 1776 Yorktown, Suite 550, Houston, TX 77056, is seeking to register securities for public sale. Mark White serves as the Chief Executive Officer.
Why It Matters
This S-1 filing indicates Nexalin Technology, Inc. is preparing to offer its securities to the public, which could lead to increased liquidity and capital for the company's operations in the electromedical sector.
Risk Assessment
Risk Level: medium — As an S-1 filing, it represents a company seeking to go public, which inherently carries risks associated with market reception and operational scaling.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Nexalin Technology, Inc. (company) — Registrant
- 0001527352 (company) — Central Index Key
- 3845 (company) — Standard Industrial Classification Code
- 275566468 (company) — IRS Number
- DE (company) — State of Incorporation
- 1776 Yorktown, Suite 550 Houston, TX 77056 (company) — Business Address
- Mark White (person) — Chief Executive Officer
- Martin S. Siegel, Esq. (person) — Agent for Service Counsel
- Warshaw Burstein, LLP (company) — Agent for Service Law Firm
- 333-283960 (dollar_amount) — SEC File Number
FAQ
What is the primary business of Nexalin Technology, Inc.?
Nexalin Technology, Inc. is primarily involved in electromedical and electrotherapeutic apparatus, as indicated by its SIC code 3845.
When was this S-1 filing submitted?
This S-1 filing was submitted on December 20, 2024.
Who is the CEO of Nexalin Technology, Inc.?
Mark White is the Chief Executive Officer of Nexalin Technology, Inc.
What is the principal executive office address?
The principal executive offices are located at 1776 Yorktown, Suite 550, Houston, TX 77056.
What is the SEC file number for this registration?
The SEC file number for this registration is 333-283960.
Filing Stats: 4,443 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2024-12-20 12:35:52
Key Financial Figures
- $0.001 — ares”) of common stock, par value $0.001 per share of Nexalin Technology, Inc. (
- $3.06 — Capital Market on December 19, 2024 was $3.06 per share. We are an “emerging g
Filing Documents
- nexalintech_s1.htm (S-1) — 372KB
- nexalintech_ex5-1.htm (EX-5.1) — 12KB
- nexalintech_ex10-19.htm (EX-10.19) — 79KB
- nexalintech_ex23-1.htm (EX-23.1) — 3KB
- nexalintech_ex107.htm (EX-FILING FEES) — 29KB
- img_001.jpg (GRAPHIC) — 11KB
- ex5-1_001.jpg (GRAPHIC) — 24KB
- ex10-19_001.jpg (GRAPHIC) — 4KB
- 0001829126-24-008446.txt ( ) — 550KB
Use of Proceeds
Use of Proceeds 29 Dividend Policy 30 September 2022 Public Offering 31 Selling Stockholders 32
Description of Securities
Description of Securities 33 Plan of Distribution 37 Legal Matters 39 Experts 39 Where You Can Find Additional Information 39 Incorporation of Certain Information by Reference 40 i ABOUT THIS PROSPECTUS This prospectus describes the general manner in which the Selling Stockholders may offer from time to time up to an aggregate of 2,798,613 shares of common stock, par value $0.001 per share (“Common Stock”), of Nexalin Technology, Inc. (the “Company”, “we”, “us” or “our”), consisting of (i) up to 347,250 shares of Common Stock issuable upon the exercise of the common stock purchase warrant that was issued to Maxim Partners, LLC (“Maxim Partners”) as compensation for its services in connection with the Company’s 2022 initial public offering; (ii) up to 2,315,000 shares of Common Stock issuable upon the exercise of the common stock purchase warrants issued to purchasers of Units (containing both a share of common stock and a common stock purchase warrant) in connection the Company’s 2022 public offering; and (iii) 136,363 shares of Common Stock issued to Maxim Partners pursuant to a renewal of its engagement agreement with the Company. You should rely only on the information contained in this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation of an offer to purchase, the shares of Common Stock offered by this prospectus, any prospectus supplement or amendments thereto in any jurisdiction to or from